2025-06-04-Jefferies-健伍（KVUE）_买入巴黎新闻相关股票_13页_774kb

Equity Research Summary: Kenvue (KVUE)

• Rating & Price Target: Buy recommendation with a $27 price target (+22% upside).
• Business Recovery Signals: Kenvue is showing signs of recovery amid destocking and cautious consumer trends. Neutrogena sales growth driven by increased marketing on feature/display activities. Allergy products saw a 4.5% sales increase year-over-year from April to mid-May.
• Reinvestment Strategy: Expected 90% reinvestment rate in 2025, aligning with US HPC peers, aimed at driving organic growth to 2-3% by 2026; reinvestment correlated with improved returns.
• Valuation Analysis: SOTP ($27/sh) based on 20-25x peer multiples. Reports suggest fair value closer to 2023 Staples peers, justifying a re-rating toward 14-15x EBITDA.
• Financial Outlook:
  • 2025 EPS unchanged at $1.14, with trimmed organic sales growth due to April destocking but positive 2H outlook.
  • Revenue projections: 15,692MM for 2025, accelerating in 2026; estimates put total return at 8.7-15.8%.
• Upside/Downside Scenarios: Base case assumes 2% organic growth in 2025 and margin expansion; growth inhibition or spending missteps lead to 19-58% valuation scenarios.
• Risks: Competition, destocking, margin pressures, product litigation; sustainability commitments noted but evaluated in ESG integration.
• Key Catalysts: Portfolio optimization, buybacks, additional litigation; pre-earnings press conference details under investigation.

[Summary based on analysis from the provided equity research report.]